Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
Exploring the companies and themes that make up this emerging and exciting new sector
DELIC HOLDINGS CORP PROVIDES DEFAULT STATUS UPDATE
Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.
Major Step Forward For PTSD Treatment And The Psychedelics Industry
A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Revitalist’s Strategic Initiatives Continue to Exceed Expectations for Execution Giving Company Record High Revenues Since Opening in 2018.
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
Red Light Holland Files International Patent Application for 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data
Red Light Holland submits a new patent application for its microdosing kits.
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.